Bumetanide
58 NDCs across 15 manufacturers|58 Generic,0 Brand
Bumetanide is used to treat acute kidney injury, ascites, edema, heart failure, hypertension and chronic kidney failure, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Feb 28, 1983, and the first generic was approved Oct 31, 1994. FDA's Orange Book lists 39 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $79 million on Bumetanide across 2.4 million claims for 571,000 beneficiaries.
Bumetanide is available as 58 NDCs from 15 manufacturers (58 generic, 0 brand), with NADAC prices from $0.11 to $0.24 per EA — the most expensive product costs about 2.3× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Active FDA drug shortage
12 Bumetanide presentations are currently listed in FDA's drug shortage database (first posted Dec 13, 2017). Shortages can move NADAC prices in the following weeks.
Total NDCs
58
58G / 0B
Manufacturers
15
competing in market
Price Spread
$0.11 – $0.24
per EA
7d Activity
avg +0.7% WoW · of 58 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Sandoz Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Loop Diuretic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
15 manufacturers producing BUMETANIDE(4 pricing outliers)
Frequently Asked Questions
What is Bumetanide used to treat?
Bumetanide is used to treat acute kidney injury, ascites, edema, heart failure, hypertension and chronic kidney failure, per the National Library of Medicine's MED-RT classification.
When did Bumetanide become available as a generic?
FDA approved the first generic Bumetanide (ANDA) on Oct 31, 1994. The Orange Book currently lists 39 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Bumetanide?
In 2024, Medicare Part D spent $79 million on Bumetanide across 2.4 million claims for 571,000 beneficiaries.
Is Bumetanide in shortage?
Yes — FDA's drug shortage database currently lists 12 Bumetanide presentations with status "Current", first posted Dec 13, 2017.
How many Bumetanide products are on the market?
The Bumetanide drug market contains 58 NDCs from 15 manufacturers — 58 generic and 0 brand products.
What is the price range for Bumetanide?
NADAC reference prices for Bumetanide range from $0.1079 to $0.2436 per EA — the most expensive product costs about 2.3× the cheapest.
Which manufacturers make Bumetanide?
15 manufacturers list Bumetanide in NADAC. Ranked by number of NDCs, the largest are Sandoz Inc. (6), Zydus Pharmaceuticals (USA) Inc. (5), Edenbridge Pharmaceuticals LLC (5), Solco Healthcare US LLC (5), Lifestar Pharma LLC (5).
How has the price of Bumetanide changed recently?
Over the past 7 days, 40 Bumetanide NDCs rose and 10 fell, with a market-wide average change of +0.7%.